However, the scientists also found that the FDA-approved drug decitabine, a chemotherapy that slows cancer cell growth, can reverse these gene edits. At low doses, decitabine reactivates the ...

Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for patients with ...

05). All 32 patients first received frontline therapy with azacitidine (61.5%), decitabine (14.4%), oral decitabine (1.5%), HMA with venetoclax (11.1%), or other HMA combinations (11.5%).